Unusual Options Activity Signals Bullish Sentiment for Pfizer Shares
Published on 01/23/2026 at 07:22 | Redaktion boerse-global.de
A surge in derivatives trading, rather than a major product announcement, has placed Pfizer in the spotlight. This activity coincides with the pharmaceutical giant’s stock reaching a five-week high of approximately $26.10. The shares also traded ex-dividend on January 23, 2026, adding another layer to the current market dynamics.
Beyond the options market, Pfizer has been actively restructuring its portfolio. The company generated $1.9 billion from the sale of its stake in ViiV Healthcare, a specialist in HIV treatments. Concurrently, it entered into a licensing agreement with Novavax, securing rights to the Matrix-M adjuvant technology. The deal involves a $30 million upfront payment, with potential milestone payments reaching up to $500 million.
Call Option Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
